<DOC>
	<DOCNO>NCT02190604</DOCNO>
	<brief_summary>This study design assess safety , tolerability , pharmacokinetics preliminary pharmacodynamics ( proof concept ) QBW251 healthy subject cystic fibrosis patient follow single multiple dos . This first-in-human proof concept study consist 4 part , Parts 1 2 healthy volunteer Parts 3 4 cystic fibrosis patient .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Preliminary Pharmacodynamics QBW251 Healthy Subjects Cystic Fibrosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Key inclusion criterion ( Parts 1 2 ) Healthy female ( nonchildbearing potential ) male subject 18 55 year age ( inclusive ) Body mass index ( BMI ) must within range 15 30 kg/m2 Oxygen saturation ( O2 ) screen must â‰¥ 96 % room air . Key exclusion criterion ( Parts 1 2 ) Use prescription drug herbal supplement within four ( 4 ) week prior dose within 5 halflives drug , whichever long Overthecounter ( OTC ) medication ( include vitamin , dietary supplement ) within two ( 2 ) week prior dose Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer Unwilling avoid direct sun exposure cover expose skin , use topical sun block wear sunglass first dose study drug end participation study Pregnant nursing ( lactate ) woman . Key inclusion criterion ( Parts 3 4 ) : Male female patient 18 65 year age ( inclusive ) confirm diagnosis cystic fibrosis per Cystic Fibrosis Foundation ( CFF ) consensus guideline Heterozygous one allele represent CFTR mutation allele must represent class III , IV , V , VI CFTR mutation ( Note : since CFTR mutation , F508del , consider either class II III mutation , heterozygous CF patient one allele contain F508del , must allele contain class III ( i.e. , F508del ) , IV , V , VI mutation ) . Patients F508del/F508del mutation include Part 3 Cohort 3 . Body mass index ( BMI ) must within range 1535 kg/m2 FEV1 Screening must 40 100 % predict ( inclusive ) NHANES/Hankinson standard Oxygen saturation ( O2 ) screen must &gt; 90 % room air . Key exclusion criterion ( Parts 3 4 ) Use herbal supplement within four ( 4 ) week prior dose within 5 halflives supplement , whichever long Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer Unwilling avoid direct sun exposure cover expose skin , use topical sun block wear sunglass first dose study drug end participation study Pregnant nursing ( lactate ) woman Women childbearing potential , UNLESS use highly effective contraception Any change concomitant medication 14 day prior screen History clinical evidence pancreatic injury pancreatitis ; clinical evidence liver disease liver injury indicate clinically significant abnormal liver function test judge investigator SGOT , SGPT , GGT , alkaline phosphatase , serum bilirubin History presence impair renal function indicate abnormal creatinine BUN value abnormal urinary constituent ( e.g. , albuminuria ) History Burkholderia cepacia respiratory tract infection ( must least two negative culture positive culture past 18 month prior screen eligible enrollment ) Sexually active male unless use condom intercourse take drug condom require use also vasectomize men order prevent delivery drug via seminal fluid . Patient currently receive ( receive within 4 week baseline visit ) VX770/Ivacaftor . History lung transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>FEV1- Forced Expiratory volume</keyword>
	<keyword>LCI - Lung Clearance Index</keyword>
	<keyword>CFTR - cystic fibrosis transmembrane conductance regulator</keyword>
</DOC>